Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Alligator Bioscience AB is a clinical-stage biotechnology company focused on developing tumor-directed immuno-oncology antibody drugs, particularly those targeting the CD40 receptor pathway. Its primary purpose is to activate the patient's immune system directly within the tumor microenvironment, overcoming immune suppression to elicit potent anti-tumor responses. The company's lead asset, mitazalimab, a CD40 agonist, is advancing toward Phase 3 development in first-line metastatic pancreatic cancer after promising Phase 2 OPTIMIZE-1 trial results, including unprecedented 24-month survival outcomes in this challenging indication. Alligator Bioscience AB maintains a robust pipeline of mono- and bispecific antibody programs designed for localized immune activation, balancing efficacy and safety. Founded in 2001 and headquartered at Medicon Village in Lund, Sweden, the company plays a significant role in advancing immunotherapies for hard-to-treat cancers, contributing to innovation in the biotechnology sector.
kr 0.17
kr 0.01 (-5.25%)
Price from 7 days ago
The business is unprofitable at the operating level (-23669.26% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 99.1% YoY. Margins deteriorated 23340.9pp alongside, both lines moving the wrong way.
Negative free cash flow of -kr 157M. The business is consuming cash, not generating it. Operating margin contracted 23340.9pp YoY, cost discipline may be slipping.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (FY)
kr 514K
▼ -99.1% YoY
Net Income (FY)
-kr 51M
▲ +78.0% YoY
Op. Margin
-23669.26%
▼ -23340.9pp YoY
ROIC
-204.90%
▲ +212.8pp YoY
Cash Flow & Balance Sheet
FCF (FY)
-kr 157M
▲ +25.9% YoY
Op. Cash Flow (FY)
-kr 130M
▲ +39.0% YoY
Net Debt
-kr 19M
Net Cash Position
Cash & Equiv.
kr 62M
3Y CAGR: -75.7%
Continue Research
Alligator Bioscience AB (ATORX.XSTO)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Alligator Bioscience AB scores 10/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Alligator Bioscience AB scores 10 out of 100 on Intrinsiqq's quality score, passing 1 of 6 checks, which makes it a lower-quality business on these measures. Recent fundamentals include a -23,669.3% operating margin and a -204.9% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full check-by-check breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh ATORX.XSTO's valuation and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.